Publication: Pyronaridine – the Current Antimalarial Standing Up to Parasite Resistance
Issued Date
2024
Resource Type
Resource Version
Accepted Manuscript
Language
eng
File Type
application/pdf
ISSN
0125-3611 (Print)
2651-0561 (Online)
2651-0561 (Online)
Journal Title
Ramathibodi Medical Journal
Volume
47
Issue
4
Start Page
34
End Page
45
Access Rights
open access
Rights
ผลงานนี้เป็นลิขสิทธิ์ของมหาวิทยาลัยมหิดล ขอสงวนไว้สำหรับเพื่อการศึกษาเท่านั้น ต้องอ้างอิงแหล่งที่มา ห้ามดัดแปลงเนื้อหา และห้ามนำไปใช้เพื่อการค้า
Rights Holder(s)
Department of Pathology Faculty of Medicine Ramathibodi Hospital Mahidol University
Bibliographic Citation
Ramathibodi Medical Journal. Vol. 47, No. 4 (Oct - Dec 2024), 34-45
Suggested Citation
Saranya Auparakkitanon Pyronaridine – the Current Antimalarial Standing Up to Parasite Resistance. Ramathibodi Medical Journal. Vol. 47, No. 4 (Oct - Dec 2024), 34-45. 45. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/110057
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Pyronaridine – the Current Antimalarial Standing Up to Parasite Resistance
Author(s)
Abstract
Pyronaridine, an aza-9-anilinoacridine schizonticide, was synthesized in China 54 years ago and since 2012 has been prescribed globally in combination with artesunate, marketed under the name Pyramax. Artesunate is an analog of artemisinin, a sesquiterpene lactone with an endoperoxide moiety, extracted from Artemisia annua L., and used as an herbal remedy in Chinese traditional medicine to treat jungle fever, also discovered in China at nearly the same time. Pyramax is one of the safest and most efficacious forms of artemisinin combination therapy (ACT) for treating uncomplicated Plasmodium falciparum malaria in adults and children. This narrative review explains the mechanism of action of pyronaridine, why it remains effective against P. falciparum even though the parasite has evolved resistance or tolerance to all other antimalarial drugs used in clinical practice, and suggests possible antiplasmodial deaza-pyronaridine (acridine) analogs that could be used should pyronaridine becomes ineffective.